Vertex Pharmaceuticals Selects Evotec's J.POD Facility for Commercial Production
Vertex Pharmaceuticals has chosen Evotec's J.POD Redmond site for the commercial manufacturing of its drug candidate, povetacicept.
Stocks · News reference
Analysts Adjust Price Targets for Evolution AB
Financial analysts from Berenberg and Morgan Stanley have updated their price targets for Evolution AB, maintaining their respective 'Hold' and 'Equal-weight' ratings.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
JPMorgan Chase Files Voting Rights Notification for Evotec SE
JPMorgan Chase & Co. disclosed that it crossed a 3% voting rights threshold in Evotec SE as of October 30, 2026.
Evotec SE Reports Third Quarter and Nine-Month 2026 Results
Evotec SE announced its financial results for the third quarter and first nine months of 2026, while adjusting its mid-term outlook.
JPMorgan Chase Crosses Voting-Rights Threshold in Evotec SE
Evotec SE disclosed that JPMorgan Chase crossed a voting-rights threshold in the company on October 23, 2026.
Evotec SE Releases Voting Rights Announcement
Evotec SE published a regulatory disclosure regarding the total number of voting rights in accordance with the German Securities Trading Act (WpHG).
Morgan Stanley Raises Price Target on Evolution AB
Morgan Stanley analyst Ed Young has increased the price target for Evolution AB (EVO) from SEK 740.00 to SEK 780.00 while maintaining an Equalweight rating.